Case File
efta-efta01816965DOJ Data Set 10CorrespondenceEFTA Document EFTA01816965
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01816965
Pages
0
Persons
0
Integrity
No Hash Available
Loading PDF viewer...
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
To:
Farkas, Andrew
From:
Jeffrey Epstein
Sent
Sun 8/16/2009 2:04:51 PM
Subject: Re: Simplest Form
seems promising.. what can i read„ assets? „ timing.? cash flow projections?
On Sun, Aug 16, 2009 at 9:57 AM, Farkas, Andrew L. <an
wrote:
W/ regards to our proposed centerline deal, we expect that equity required for initial
acquisition, deal cost and working capital requirement (before playing in the cmbs portfolio
itself) will approximate $115mm. This wld give us control of platform, cmbs portfolios, etc.,
ad would eliminate virtually all of the roughly $2.6bb of total liabilities etc (project that
successor enterprises, split into three separate corporate silos, wld assume aggregate of
roughly $80mm of senior secure debt, i/o for approx 5 yrs and that there would be no other
material remaining liabilities). Deal w/ investors will be all but identical to deal w/ founding
insignia investors. Everyone gets pre-emptives, anti diultions, tags, drags, etc. Splits in insignia
private equity deal was 95/5 tii roc, 90/10 til 8% pref, 70/30 til greater of 200% or 20%/yr
simple and 50/50 thereafter. 2 steps: seedco where investors share in pursuit costs (all of
which are reimbursed by second round if deal closes successfully) approxomating $12mm.
Seedco investors get 50% of break up fee and 100% of cost reimbursement from target if deal
fails and get a 5% ownerhship for free plus pre-emptive right on 45% of all equity in
acquisition if deal is successful. Happy to explain on phone in detail if you like, but thought
this wld be helpful. Just need to know if this works for you.
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments.
EFTA_R1_00188549
EFTA01816965
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.